Six months after selling its critical care business to refocus on rare diseases and oncology, EUSA Pharma has made its first move into those markets by licensing a Janssen product for a rare blood disorder.
EUSA Pharma, a UK-based company specializing in oncology and rare disease, has acquired the worldwide rights to idiopathic multicentric Castleman's disease (iMCD) therapy Sylvant (siltuximab) from Janssen Sciences Ireland UC for $115m in cash.
Funded by the July divestment of its critical care business (see sidebar), EUSA is making good on its strategy to...
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck & Co. won European Commission approval for Winrevair on top of other medicines for pulmonary arterial hypertension and expects an initial EU launch in Germany.
The company, in its new profitable era, is bringing in new leadership, with Amgen VP of medical affairs for rare diseases Greg Friberg and recently retired Roche Partnering head James Sabry.
Bluebird, Vertex and Sarepta are starting to see some commercial gene therapy traction and expect momentum to pick up in the second half, while hemophilia remains a challenging area.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
